http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008024026-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ced57a347b588ef4bdf841fb5338e3f4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4738 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2007-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3e0db6b13d513dc1071798f13b80ae5 |
| publicationDate | 2008-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008024026-A3 |
| titleOfInvention | Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer |
| abstract | The present invention provides the use of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters, in combination with antiandrogenic hormonotherapy, for the treatment, prophylaxis and relapse prevention of prostate cancer. A method of treatment or prophylaxis of prostate cancer comprises the steps of (a) administration of an effective amount of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester to a patient in need thereof and (b) hormonotherapy aimed at decreasing androgen action. Further, a method of inducing or increasing the sensitivity of prostate cancer to hormone therapy aimed at decreasing androgen action is provided, wherein the method comprises administration of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester. |
| priorityDate | 2006-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.